Seeking Alpha

Merck (MRK +3.3%) says that the Data Safety Monitoring Board will allow the company to continue...

Merck (MRK +3.3%) says that the Data Safety Monitoring Board will allow the company to continue with its large-scale trial of its blockbuster Vytorin cholesterol drug, indicating that no safety issues have come up. Some analysts had hoped that the trial would already have demonstrated Vytorin's effectiveness and so could be halted. Alas, the study will continue until September 2014. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|